EGFR and squamous cell carcinoma: Similarly, preclinical combination studies of alpelisib and cetuximab inhibited EGFR phosphorylation, resulting in inhibition of mTOR activation and subsequent cell death in squamous cell carcinoma cells and tumors (Elkabets et al. 2015).